GLUCOCORTICOID THERAPY DECREASES SERUM LIPOPROTEIN(A) CONCENTRATION IN RHEUMATIC DISEASES

被引：10

作者：

AOKI, K ^{[1
]}

KAWAI, S ^{[1
]}

机构：

[1] SAITAMA MED CTR,SAITAMA MED SCH,DEPT INTERNAL MED 2,SAITAMA,JAPAN

来源：

INTERNAL MEDICINE | 1993年 / 32卷 / 05期

关键词：

RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; STILLS DISEASE WITH ADULT ONSET; CHOLESTEROL; APOLIPOPROTEIN-B; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL;

D O I：

10.2169/internalmedicine.32.382

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lipoprotein(a) has been strongly suggested to be a risk factor for atherosclerosis. However, its metabolism and/or regulation by drug treatment still remain unknown. We therefore studied the effects of glucocorticoid therapy on serum lipoprotein(a) in rheumatic diseases. Although the glucocorticoid treatment increased the total serum cholesterol, high-density lipoprotein cholesterol and apolipoprotein B concentrations, it reduced the serum lipoprotein(a) concentration (mean, 40%) in a dose-dependent manner in 9 patients with rheumatic diseases without nephrotic syndrome. Similar results were observed in 2 patients who did have nephrotic syndrome. It is assumed that the increase of total cholesterol and apolipoprotein B in serum levels are atherogenic, whereas the increase of high-density lipoprotein cholesterol and the decrease of lipoprotein(a) are protective for atherosclerosis. The clinical outcome of the concomitant results in lipid metabolism in the development of atherosclerosis remains to be studied.

引用

页码：382 / 386

页数：5

共 18 条

[1] Bulkley B.H., Roberts W.C., The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy, Am J Med, 58, (1975)
[2] Ichikawa Y., Toguchi T., Kawagoe M., Saito E., Abe T., Homma M.E.C.G., abnormalities in steroid-treated rheumatoid patients, Lancet, 2, (1977)
[3] Nashel D.J., Is atherosclerosis a complication of long-term corticosteroid treatment?, Am J Med, 80, (1986)
[4] Henkin Y., Como J.A., Oberman A., Secondary dyslipidemia: inadvertent effects of drugs in clinical practice, JAMA, 267, (1992)
[5] Rhoads G.G., Dahlen G., Berg K., Morton N.E., Dannenberg A.L., Lp(a) lipoprotein as a risk factor for myocardial infarction, JAMA, 256, (1986)
[6] Murai A., Miyahara T., Fujimoto N., Matsuda M., Kameyama M., Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction, Atherosclerosis, 59, (1986)
[7] Warnick G.R., Benderson J., Albers J.J., Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol, Clin Chem, 28, (1982)
[8] Ikeda T., Shibuya Y., Senba U., Et al., Automated immunoturbidimetric analysis of six plasma apolipoproteins: correlation with radial immunodiffusion assays, J Clin Lab Anal, 5, (1991)
[9] Morrisett J.D., Guyton J.R., Gaubatz J.W., Gotto A.M., Lipoprotein(a): structure, metabolism and epidemiology, Plasma Lipoproteins, (1987)
[10] Karadi I., Romics L., Palos G., Et al., Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin, Clin Chem, 35, (1989)

← 1 2 →